Plexr / Plasma

Plexr and other plasma-pen treatments are often described as “non-surgical skin tightening”.

That phrase is technically understandable and clinically incomplete.

No scalpel is used.

But tissue is still deliberately injured.

Plasma devices generate an electrical discharge through the air between a small electrode and the skin. The ionised gas allows energy to cross that gap and create highly localised thermal damage at the tissue surface.

Small dots of coagulated or vaporised tissue are produced according to the device and technique. Those areas crust and subsequently heal.

The resulting contraction and wound-healing response can improve selected superficial laxity and can also be used with some systems to destroy certain benign skin lesions.

This makes plasma technology interesting.

It does not make it a blood treatment, PRP, a cold-plasma wellness facial or a surgery-equivalent procedure without surgical risk.

So before I discuss the number of plasma dots, I want to define the real problem: are we trying to create controlled superficial contraction in mild skin excess, destroy a diagnosed lesion, or compensate for an anatomical problem that plasma cannot actually correct?

Plasma pen does not inject plasma into the skin

The word plasma creates immediate confusion because medicine uses it in several unrelated ways.

Blood plasma is the liquid component of blood.

Platelet-rich plasma is an autologous blood-derived injectable.

Plasma in a Plexr-type device refers to an ionised gas state generated by an electrical field.

No blood plasma is being transferred.

No platelets are being injected.

The treatment mechanism is electrical and thermal.

Plexr is not PRP without a needle.

It is a controlled electrosurgical tissue-injury technology.

The word “fibroblast” is also more marketing shorthand than treatment anatomy

Plasma-pen procedures are sometimes called plasma fibroblast treatments.

The rationale is that wound healing following controlled thermal injury can activate fibroblasts and subsequent collagen remodelling.

That does not mean the plasma arc selectively locates fibroblasts and stimulates them without injuring surrounding tissue.

The immediate event is tissue damage.

The fibroblast response occurs later as part of repair.

I prefer to describe the full mechanism because otherwise the procedure sounds like a gentle cellular stimulation treatment rather than a controlled superficial burn.

Plasma exeresis works through an electrical arc across a small air gap

The treatment tip is generally held very close to the skin rather than placed deeply into tissue.

The electrical potential ionises the intervening air and creates a plasma arc.

Energy is transferred to the superficial tissue, producing rapid heating and local coagulation or destruction.

The small carbonised points visible afterwards are therefore not pigment deposited by the device.

They are treatment sites.

This mechanism explains both the contraction that can be useful and the crusting, erythema and pigment complications that can follow.

Plexr is not the same thing as cold atmospheric plasma research

Plasma medicine is a broad scientific field.

Cold atmospheric plasma has been investigated for antimicrobial effects, wound healing and other biomedical applications using devices designed to minimise thermal injury.

Plexr-type aesthetic plasma exeresis uses a different treatment objective.

It intentionally creates focal tissue destruction or coagulation.

Evidence from cold-plasma wound research should therefore not automatically be used to validate aesthetic claims for a plasma pen.

They share the physical concept of ionised gas.

They do not necessarily deliver the same biological exposure.

The FDA device classification is more revealing than the phrase “plasma facial”

In the United States, low-power Plasma Pen devices cleared within the relevant electrosurgical category are classified as devices for skin-lesion destruction.

The FDA technical description states that these devices generate an electrical arc in ambient air between a probe tip and the skin, causing intended tissue damage.

I think that wording is useful because it removes the ambiguity.

The treatment is not simply energising skin cells.

It works because tissue is intentionally injured.

Any treatment whose mechanism is “intended tissue damage” deserves the same respect for anatomy, wound healing and complication prevention as other destructive technologies.

FDA clearance of a plasma-pen device should not be expanded into every cosmetic claim made about plasma

This distinction matters.

A device can have US 510(k) clearance for a particular device category or indication.

That does not automatically establish that every commercial claim around nonsurgical blepharoplasty, facial lifting, scar removal or wrinkle treatment has been individually proven and cleared.

Likewise, regulatory status in the United States does not define legal status in Türkiye.

I keep device clearance, local regulation and clinical evidence as separate questions.

The treatment should not gain indications simply because the machine itself can legally exist on the market.

Mild upper-eyelid dermatochalasis is one of the best-studied aesthetic plasma indications

Much of the published aesthetic plasma-exeresis literature concerns the upper eyelid.

The reason makes anatomical sense.

Mild excess upper-eyelid skin can sometimes be reduced visually by creating a controlled pattern of focal superficial contraction.

Small clinical studies have reported improvement in dermatochalasis, palpebral laxity and patient-rated appearance after a series of treatments.

This is enough for me to consider plasma exeresis a legitimate nonsurgical option in selected mild or moderate cases.

It is not enough for me to call it equivalent to blepharoplasty.

The evidence base for upper-eyelid treatment is promising and still relatively small

A pilot study published in 2018 included ten patients and reported both clinical improvement and confocal evidence of collagen remodelling after three plasma-exeresis treatments.

A later clinical trial included forty women and found improvement in measured eyelid laxity after three sessions.

Another periorbital trial included fifty-six women and also reported improvement in dermatochalasis and laxity.

These are useful clinical signals.

They are still small studies compared with the evidence base and long-term experience available for surgical upper blepharoplasty.

And an observational study of sixteen patients found that while early satisfaction was reasonable, enthusiasm about undergoing the procedure again decreased during follow-up.

That is exactly the kind of evidence I want visible in the discussion.

A treatment can work without being the right choice for everyone.

“Non-surgical blepharoplasty” should not imply that the same anatomy is being corrected

Surgical blepharoplasty can excise redundant skin, manage selected fat compartments and address anatomy under direct visual control.

Plasma exeresis creates superficial focal tissue injury and contraction.

Those mechanisms overlap only partly.

A patient with mild skin redundancy may obtain enough improvement from contraction that surgery is unnecessary for their goal.

A patient with substantial dermatochalasis, major fat prolapse or another structural problem may not.

The choice should depend on how much correction is required rather than on whether one treatment carries the more attractive word nonsurgical.

True eyelid ptosis is not a plasma-pen problem

This distinction is fundamental.

Dermatochalasis refers to redundant eyelid skin.

Ptosis refers to abnormal position of the eyelid margin and can involve the mechanism responsible for elevating the eyelid.

A patient can have both.

Shrinking superficial skin does not repair levator dysfunction.

If the eyelid margin itself sits too low, that functional anatomy deserves ophthalmic or oculoplastic assessment.

Reducing skin above a drooping eyelid does not correct the mechanism that makes the eyelid droop.

Brow ptosis can also masquerade as excess upper-eyelid skin

The brow contributes to the amount of tissue resting over the upper eyelid.

If the brow has descended, the patient may interpret the resulting heaviness entirely as eyelid skin excess.

Removing or contracting more lid skin does not reposition the brow.

This is why I assess the upper face as a unit rather than drawing plasma dots wherever a fold is visible.

Lower-eyelid treatment requires even more restraint

The lower eyelid has very thin skin and an important relationship with lid position, orbital fat and the supporting canthal structures.

A patient may have fine crepey skin, but another may have fat prolapse, edema or true lower-lid laxity.

Superficial contraction cannot correct every one of these mechanisms.

Excessive scar contraction around the lower eyelid is also something I do not want to provoke casually.

The closer treatment comes to a structure whose normal position matters for ocular protection, the higher my indication threshold becomes.

The eyelid is not ordinary facial skin

The eye must open, close and protect the ocular surface continuously.

The skin is thin and the treatment area sits immediately beside the globe.

This means small technical errors can matter disproportionately.

Eye protection, local anaesthesia, device position and operator understanding of eyelid anatomy are not minor details.

Aesthetic convenience should never reduce an eyelid procedure to a salon facial.

The topical anaesthetic can create its own ocular risk if used carelessly

A published case report describes bilateral chemical eye injury after topical EMLA anaesthetic entered the eyes during preparation for plasma-fibroblast skin tightening.

The complication was not caused directly by the plasma arc.

That is precisely why the case matters.

Procedure safety includes everything required to perform the procedure, not only the device itself.

A complication does not become irrelevant because it occurred during preparation rather than during the plasma pulse.

Crusting is part of the wound-healing process

After plasma exeresis, multiple small treatment points can darken and form crusts.

Swelling is particularly noticeable around the eyelids.

Redness, tenderness and itching can also occur during recovery.

The patient should therefore not be told there is no downtime simply because no incision has been sutured.

The wound is smaller and distributed differently from surgery.

It is still a wound.

The crusts should not be deliberately removed early

Picking treatment sites converts controlled wound healing into additional mechanical trauma.

This can increase inflammation, infection risk and subsequent pigmentation or scarring.

The same principle applies after chemical peeling and ablative resurfacing.

Once tissue injury has been created deliberately, the recovery phase has to be respected as part of the treatment.

Post-inflammatory hyperpigmentation is a real plasma-exeresis complication

The visible plasma dots represent thermal epidermal injury.

Inflammation can stimulate melanogenesis during healing.

Published cases document persistent periorbital post-inflammatory hyperpigmentation after plasma exeresis.

This matters particularly in darker or pigment-reactive skin.

I therefore do not accept the claim that because the plasma arc is extremely focal, pigment risk is negligible.

Focal injury can still create focal pigment.

Skin tone changes the trade-off even though plasma is not a pigment laser

The plasma arc is not targeting melanin through selective photothermolysis.

But the wound it creates still heals through inflammation.

Melanocytes respond to that inflammation.

Patients with a strong history of PIH therefore deserve additional caution even though the device is not using a pigment-absorbing wavelength.

The mechanism of pigment risk is inflammatory rather than optical.

Hypopigmentation and scarring are the opposite end of the same depth problem

If thermal injury extends beyond the intended superficial level, normal melanocyte function and dermal architecture can be damaged.

This can lead to persistent lighter spots or textural scarring.

The theoretical attraction of plasma is that injury can be created in very small controlled points.

That advantage disappears if the dots are made too deep, too dense or repeatedly overlapped.

Dot density is a dose

A plasma pattern leaves untreated tissue between individual injury points.

This allows healing from the surrounding skin.

But as treatment dots become more densely packed, the total fraction of injured tissue increases.

The patient therefore does not receive the same biological treatment simply because every individual dot is small.

Small injuries can become a large injury when enough of them are placed close together.

I consider total treatment density alongside the intensity of each plasma application.

Repeating passes over the same area can change the depth unpredictably

Once tissue has already been thermally altered, applying more energy over the same point does not necessarily create a neat second identical treatment.

The local electrical and thermal environment has changed.

This increases the risk that attempts to produce greater contraction become deeper injury.

I do not use repeated burning as a substitute for selecting a patient whose skin excess is within the capability of the method.

More contraction is not always better around a mobile structure

The eyelid needs enough skin to close normally.

The perioral area needs to move during speech and eating.

Any contraction-based treatment needs to preserve function.

This is why “maximum tightening” is a poor endpoint around structures designed to move.

A small residual fold can be anatomically preferable to an over-contracted region.

Benign skin lesions can be treated with plasma, but diagnosis comes first

Plasma devices can destroy selected superficial benign lesions.

A 2024 retrospective ophthalmic study reported successful plasma-exeresis removal of benign eyelid lesions in 66 patients with favourable outcomes.

This can be a useful clinical application.

But a device capable of making a lesion disappear visually creates a responsibility.

Before destroying a pigmented or unusual lesion, I want to know that destruction is appropriate.

A lesion that requires histopathology should not be vaporised first and diagnosed from memory afterwards.

“It is only a skin tag” is not always enough diagnostic certainty

Patients commonly self-diagnose small lesions as skin tags, moles or sunspots.

Many of them are benign.

Some require a different evaluation.

The cosmetic convenience of plasma destruction should therefore follow clinical diagnosis rather than replace it.

This is particularly important for pigmented, changing, ulcerated or otherwise atypical lesions.

Xanthelasma is one possible plasma indication but not simply an aesthetic surface spot

Small studies have reported successful plasma treatment of xanthelasma palpebrarum.

The lesion can be cosmetically removed through several methods.

Xanthelasma can also be associated with lipid disorders in some patients.

Removing the visible plaque therefore does not necessarily end the medical conversation.

Recurrence is also possible regardless of the removal technique.

Plasma is not automatically superior to laser because there is no laser beam

Fractional CO₂ and other ablative technologies can also create controlled thermal injury and contraction around the eyelids or skin.

Plasma uses a different energy-delivery method.

Neither technology is universally superior.

Laser parameters, plasma density, skin type, desired depth, downtime and operator experience all influence the trade-off.

I choose between mechanisms rather than between fashionable device categories.

Plasma is not automatically safer than surgery because there is no incision

Surgery creates an incision and can directly remove or reposition tissue.

Plasma avoids that surgical wound but creates multiple thermal wounds instead.

The risk categories are therefore different rather than absent.

Blepharoplasty has surgical risks such as bleeding, scar problems, asymmetry, dry-eye exacerbation and lid-position issues.

Plasma has thermal-injury, pigment, scar and recovery risks and offers less direct control over substantial tissue excess.

The right comparison is not “risk versus no risk”.

It is which risk–benefit profile matches the size of the problem.

The non-surgical option can become the more complicated option when the anatomy needs surgery

A patient with substantial upper-eyelid skin excess may require several plasma sessions to produce an incomplete correction.

Each session creates another inflammatory and pigment exposure.

The patient may ultimately proceed to surgery anyway.

That does not mean plasma was inherently wrong.

It may mean the desire to avoid surgery was given greater weight than the scale of the anatomy.

A less invasive treatment is not automatically a more conservative treatment if it has to be repeated aggressively to chase a surgical-scale result.

A first session should be allowed to heal before another injury is added

Plasma-exeresis studies often use staged sessions separated by several weeks.

This reflects the biology of wound healing and contraction.

I want the crusting resolved, inflammation settled and pigment response visible before deciding what the tissue needs next.

If significant improvement continues during remodelling, waiting can be part of the treatment.

The residual problem after one or two sessions may no longer be a plasma problem

Mild skin laxity can improve while a deeper fat pad remains.

A superficial fold can reduce while brow descent becomes more obvious.

A lesion can disappear while another lesion still requires diagnosis.

The treatment plan should evolve.

Repeating the same plasma pattern simply because some improvement occurred previously can become treatment drift.

Home plasma pens raise a fundamentally different safety concern

The treatment mechanism is controlled electrical tissue destruction.

That is not something I regard as equivalent to a home LED mask or an ordinary skincare device.

Depth, density, anatomical location and lesion diagnosis all matter.

Using a destructive device without training can create burns, scars, pigment change and injury to delicate structures.

The apparent simplicity of making tiny dots should not obscure what each dot biologically represents.

A salon setting does not change the anatomy of the eyelid

Plasma pens have become popular outside conventional medical practice partly because they do not require an operating theatre.

The absence of an operating theatre does not make eyelid anatomy less consequential.

A procedure near the eye still needs appropriate patient selection, ocular awareness, infection control and complication management.

A complication does not become easier to treat because the original procedure was marketed as beauty rather than medicine.

What a good Plexr / plasma result means to me

In a correctly selected upper eyelid, modest skin redundancy may become less obvious after healing and contraction.

Selected fine superficial lines may improve.

A properly diagnosed benign lesion may be removed with limited collateral injury.

I do not expect plasma dots to correct true ptosis, reposition a descended brow, remove large fat pads or reproduce the predictability of surgical tissue excision in substantial dermatochalasis.

I also do not judge the treatment by how dramatic the crusting looks.

The ideal result comes from the smallest controlled injury capable of producing enough contraction or lesion destruction to solve the defined problem.

When Plexr / plasma treatment makes sense to me

I am most comfortable considering plasma exeresis for selected mild-to-moderate superficial skin redundancy and appropriately diagnosed benign superficial lesions when the device, operator and indication are clear.

I use a higher threshold around the eyelids because normal position and function matter.

I become less enthusiastic when significant dermatochalasis requires substantial tissue removal, true ptosis or brow descent is present, pigmentation risk is high, a lesion lacks diagnostic certainty or repeated plasma treatment is being used to avoid acknowledging that the problem has become surgical.

Plasma technology is neither a miracle pen nor meaningless marketing.

It is a real tissue-injury technology with a relatively young aesthetic evidence base.

That is exactly how I think it should be used: where a small controlled injury is sufficient, with enough respect for the tissue to know when it is not.

Frequently asked questions

What is Plexr?

Plexr is a plasma-exeresis technology in which an electrical discharge ionises air between the device tip and skin, producing focal thermal tissue injury and contraction or destruction.

Is plasma treatment the same as PRP?

No. PRP is derived from the patient’s blood and contains platelets. Plasma-pen treatment uses ionised gas and electrical energy; no blood plasma is injected.

Why is it called plasma fibroblast treatment?

Controlled thermal injury triggers wound healing and subsequent fibroblast activity, but the device does not selectively stimulate fibroblasts without damaging tissue. “Fibroblast” describes part of the later repair response.

Is Plexr really non-surgical?

There is no scalpel incision or conventional surgical excision, so it is commonly described as nonsurgical. It still creates multiple deliberate thermal wounds and therefore has healing, pigment and scar risks.

Can Plexr replace upper-eyelid blepharoplasty?

It can improve selected mild-to-moderate dermatochalasis in small clinical studies. It does not offer the same ability as surgery to directly remove substantial redundant skin or manage deeper anatomy.

Can Plexr treat eyelid ptosis?

No. True ptosis involves eyelid position and the mechanism that elevates the eyelid. Superficial skin contraction does not repair levator dysfunction.

Can Plexr treat eye bags?

It does not remove prolapsed orbital fat in the same way surgical lower blepharoplasty can. A bag caused primarily by fat or edema needs a different assessment.

How strong is the evidence?

Several small clinical and observational studies report improvement in upper-eyelid dermatochalasis and periorbital laxity, but the evidence base remains much smaller and less mature than that for conventional blepharoplasty.

Does treatment stimulate collagen?

Small clinical and confocal studies demonstrate collagen-remodelling changes after plasma exeresis. This follows controlled thermal injury and should not be interpreted as unlimited tightening potential.

What does recovery look like?

Swelling, redness, itching and multiple small crusted treatment points are common during early healing. The crusts should generally be allowed to separate naturally.

Can Plexr cause pigmentation?

Yes. Post-inflammatory hyperpigmentation after periorbital plasma exeresis has been reported and is an important consideration in pigment-reactive skin.

Can plasma treatment cause scars?

Yes. Excessive depth, density, infection or abnormal healing can result in textural scarring or pigment change even though individual treatment points are small.

Can Plexr remove skin lesions?

Selected appropriately diagnosed benign superficial lesions can be treated with plasma devices, and published clinical studies report successful lesion removal. Diagnostic uncertainty should be resolved before destructive treatment.

Is an FDA-cleared Plasma Pen approved for nonsurgical blepharoplasty?

FDA device clearance is indication-specific. In the United States, relevant low-power plasma devices are classified as electrosurgical devices for skin-lesion destruction; this should not automatically be interpreted as FDA validation of every aesthetic eyelid-tightening claim.

Can I use a plasma pen at home?

I would not recommend self-treatment with a device whose mechanism is electrical tissue destruction, particularly around the eyes. Depth, density, diagnosis and anatomical safety are central to the procedure.

When would you recommend surgical blepharoplasty instead?

Surgery becomes more coherent when skin excess is substantial, deeper fat or structural anatomy requires direct treatment, true eyelid malposition exists or repeated superficial contraction would be unlikely to produce the desired correction.

When would you recommend no plasma treatment?

I would redirect treatment when the diagnosis is uncertain, the desired correction exceeds superficial contraction, pigment or scar risk is disproportionate to the benefit, or the treatment is being performed without adequate anatomical and complication-management expertise.